Latest news with #Nature'sSunshine
Yahoo
4 days ago
- Business
- Yahoo
1 Safe-and-Steady Stock with Exciting Potential and 2 to Question
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. Finding the right balance between safety and returns isn't easy, which is why StockStory is here to help. That said, here is one low-volatility stock that could offer consistent gains and two stuck in limbo. Rolling One-Year Beta: 0.77 Started on a kitchen table in Utah, Nature's Sunshine (NASDAQ:NATR) manufactures and sells nutritional and personal care products. Why Are We Cautious About NATR? Flat sales over the last three years suggest it must innovate and find new ways to grow Modest revenue base of $456.6 million gives it less fixed cost leverage and fewer distribution channels than larger companies Earnings per share fell by 20.6% annually over the last three years while its revenue was flat, showing each sale was less profitable Nature's Sunshine's stock price of $14.13 implies a valuation ratio of 18.5x forward P/E. Dive into our free research report to see why there are better opportunities than NATR. Rolling One-Year Beta: 0.45 The first homebuilder to be listed on the NYSE, KB Home (NYSE:KB) is a homebuilding company targeting the first-time home buyer and move-up buyer markets. Why Do We Avoid KBH? Backlog has dropped by 22.9% on average over the past two years, suggesting it's losing orders as competition picks up Earnings per share have dipped by 5.3% annually over the past two years, which is concerning because stock prices follow EPS over the long term Free cash flow margin dropped by 5.5 percentage points over the last five years, implying the company became more capital intensive as competition picked up At $52.29 per share, KB Home trades at 6.6x forward P/E. Read our free research report to see why you should think twice about including KBH in your portfolio, it's free. Rolling One-Year Beta: 0.32 With over 100 million people served across its various businesses and a workforce of more than 400,000, UnitedHealth Group (NYSE:UNH) operates a health insurance business and Optum, a healthcare services division that provides everything from pharmacy benefits to primary care. Why Is UNH a Top Pick? Massive revenue base of $410.1 billion gives it meaningful leverage when negotiating reimbursement rates Share buybacks catapulted its annual earnings per share growth to 13.1%, which outperformed its revenue gains over the last five years ROIC punches in at 21.6%, illustrating management's expertise in identifying profitable investments UnitedHealth is trading at $300.85 per share, or 9.7x forward P/E. Is now the time to initiate a position? See for yourself in our full research report, it's free. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
02-06-2025
- Business
- Yahoo
Why Nature's Sunshine (NATR) Shares Are Falling Today
Shares of wellness products company Nature's Sunshine (NASDAQ:NATR) fell 7.2% in the morning session after CEO Terrence Moorehead, announced his decision to step down from his role. The board also announced the search for his successor, and Moorehead will remain in his role until a new CEO is appointed. This interim period introduces leadership uncertainty, something the market generally dislikes. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Nature's Sunshine? Access our full analysis report here, it's free. Nature's Sunshine's shares are quite volatile and have had 17 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. Nature's Sunshine is down 1.8% since the beginning of the year, and at $14.30 per share, it is trading 18% below its 52-week high of $17.43 from November 2024. Investors who bought $1,000 worth of Nature's Sunshine's shares 5 years ago would now be looking at an investment worth $1,527. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Sign in to access your portfolio
Yahoo
20-05-2025
- Business
- Yahoo
NATR Q1 Earnings Call: Outperformance Driven by Asia-Pacific and Europe Amid Tariff Uncertainty
Wellness products company Nature's Sunshine (NASDAQ:NATR) announced better-than-expected revenue in Q1 CY2025, with sales up 2% year on year to $113.2 million. The company expects the full year's revenue to be around $457.5 million, close to analysts' estimates. Its non-GAAP profit of $0.25 per share was 51.5% above analysts' consensus estimates. Is now the time to buy NATR? Find out in our full research report (it's free). Revenue: $113.2 million vs analyst estimates of $109.3 million (2% year-on-year growth, 3.6% beat) Adjusted EPS: $0.25 vs analyst estimates of $0.17 (51.5% beat) Adjusted EBITDA: $10.97 million vs analyst estimates of $9.75 million (9.7% margin, 12.5% beat) The company reconfirmed its revenue guidance for the full year of $457.5 million at the midpoint EBITDA guidance for the full year is $41 million at the midpoint, below analyst estimates of $42.98 million Operating Margin: 5.4%, up from 4.2% in the same quarter last year Free Cash Flow was $1.5 million, up from -$1.5 million in the same quarter last year Market Capitalization: $272.9 million Nature's Sunshine's first quarter results were shaped by continued strength in Asia-Pacific and Europe, as well as stabilization efforts in North America. Management credited growth in Japan and Taiwan to strategic marketing, a focus on high-velocity products, and expanded digital offerings, noting that digital sales rose 19% year over year. CEO Terrence Moorehead emphasized that proactive supply chain measures and inventory buildup helped the company manage new tariff risks without immediate price increases to customers. Looking ahead, management reaffirmed its full-year revenue guidance, citing confidence in ongoing demand and the resilience of its supply chain. CFO Shane Jones noted that the company's outlook remains conservative due to macroeconomic volatility and potential tariff impacts, but expects modest gross margin improvement and stable SG&A expenses. Moorehead stated, 'We've tried to do our homework on our end to make sure that we've done everything that we can do to prepare to potential impact of tariffs.' Nature's Sunshine's management focused on operational execution and regional momentum as key drivers behind Q1's performance. Outperformance versus analyst expectations was attributed to international growth, digital expansion, and effective cost controls, while the company's proactive response to tariff risks was a recurring theme. Asia-Pacific momentum: The region saw double-digit local currency growth, with Japan and Taiwan both delivering over 18% sales increases, driven by a targeted marketing mix and growth-focused product strategy. Europe growth strategies: Central Europe's 16% sales rise was supported by the power line product focus and expansion into the Baltic states, illustrating disciplined execution and market development. North America stabilization: Despite a year-over-year decline, North America achieved its third consecutive quarter of sequential order growth, aided by organizational changes and improved digital capabilities. Digital and autoship adoption: Digital sales outpaced the broader supplement industry's growth, and the Subscribe & Thrive autoship program accounted for about 26% of total sales, supporting recurring revenue. Tariff mitigation measures: The company increased raw and finished goods inventory, diversified suppliers, and enforced pricing contracts to minimize tariff exposure and supply chain disruption. Management expects ongoing uncertainty from tariffs and consumer sentiment to shape results this year, but highlights digital growth and cost discipline as key levers. Strategic investments in digital tools and field support are expected to foster resilience and incremental growth across markets. Digital expansion focus: The rollout of new digital toolkits in North America and continued investment in e-commerce capabilities are expected to drive customer acquisition and retention. Inventory and supply chain agility: Elevated inventory levels and supplier diversification are designed to protect margins and service levels if tariff or trade conditions deteriorate. Cost management discipline: Continued scrutiny of SG&A expenses and margin improvement initiatives are projected to support operating profit even in a challenging macroeconomic environment. Brian Holland (Davidson): Asked if guidance assumes a worsening macro backdrop or a continuation of current trends. Management said the midpoint reflects ongoing instability, while the upper end assumes Q1 trends continue. Brian Holland (Davidson): Inquired about the digital toolkit launch timing and risk of order disruption. CEO Moorehead said it remains on track for the second half of the year and will not disrupt practitioner workflows. Susan Anderson (Canaccord Genuity): Asked about sustaining momentum in Europe and Asia given strong recent comps. Management sees continued opportunity but acknowledged tougher comparisons in the back half of the year. Susan Anderson (Canaccord Genuity): Questioned strategies for North America practitioner and retailer channels. Moorehead highlighted new leadership, field fundamentals, and digital tools as key to improving performance. Susan Anderson (Canaccord Genuity): Sought clarity on gross margin and SG&A cadence. CFO Jones expects modest sequential gross margin improvement and steady quarterly SG&A at $40–42 million. In the quarters ahead, the StockStory team will monitor (1) the rollout and practitioner adoption of new digital toolkits in North America, (2) whether Asia-Pacific and Europe can sustain their growth trajectory against tougher year-over-year comparisons, and (3) the effectiveness of inventory and supply chain strategies in mitigating tariff-related cost pressures. We will also watch for evidence that digital and autoship programs continue to drive recurring revenue. Nature's Sunshine currently trades at a forward P/E ratio of 19.2×. At this valuation, is it a buy or sell post earnings? Find out in our free research report. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
Yahoo
15-05-2025
- Business
- Yahoo
Q1 Earnings Outperformers: Nature's Sunshine (NASDAQ:NATR) And The Rest Of The Personal Care Stocks
As the craze of earnings season draws to a close, here's a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at personal care stocks, starting with Nature's Sunshine (NASDAQ:NATR). While personal care products products may seem more discretionary than food, consumers tend to maintain or even boost their spending on the category during tough times. This phenomenon is known as "the lipstick effect" by economists, which states that consumers still want some semblance of affordable luxuries like beauty and wellness when the economy is sputtering. Consumer tastes are constantly changing, and personal care companies are currently responding to the public's increased desire for ethically produced goods by featuring natural ingredients in their products. The 11 personal care stocks we track reported a strong Q1. As a group, revenues beat analysts' consensus estimates by 2.3% while next quarter's revenue guidance was 5.5% below. Thankfully, share prices of the companies have been resilient as they are up 6% on average since the latest earnings results. Started on a kitchen table in Utah, Nature's Sunshine (NASDAQ:NATR) manufactures and sells nutritional and personal care products. Nature's Sunshine reported revenues of $113.2 million, up 2% year on year. This print exceeded analysts' expectations by 3.6%. Overall, it was a strong quarter for the company with an impressive beat of analysts' EPS estimates and a solid beat of analysts' EBITDA estimates. '2025 got off to a strong start, as first quarter revenue came in at $113 million, up 5% on a constant currency basis, and adjusted EBITDA came in at $11 million, up 20% versus prior year,' said Terrence Moorehead, CEO of Nature's Sunshine. Nature's Sunshine delivered the weakest full-year guidance update of the whole group. Interestingly, the stock is up 15% since reporting and currently trades at $14.33. Is now the time to buy Nature's Sunshine? Access our full analysis of the earnings results here, it's free. Co-founded by actress Jessica Alba, The Honest Company (NASDAQ:HNST) sells diapers and wipes, skin care products, and household cleaning products. The Honest Company reported revenues of $97.25 million, up 12.8% year on year, outperforming analysts' expectations by 5.7%. The business had an exceptional quarter with an impressive beat of analysts' EPS estimates and a solid beat of analysts' EBITDA estimates. The Honest Company achieved the fastest revenue growth among its peers. The market seems happy with the results as the stock is up 5.7% since reporting. It currently trades at $5.06. Is now the time to buy The Honest Company? Access our full analysis of the earnings results here, it's free. Boasting brands such as Banana Boat, Schick, and Skintimate, Edgewell Personal Care (NYSE:EPC) sells personal care products in the skin and sun care, shave, and feminine care categories. Edgewell Personal Care reported revenues of $580.7 million, down 3.1% year on year, falling short of analysts' expectations by 1.8%. It was a slower quarter as it posted a miss of analysts' organic revenue estimates and full-year EBITDA guidance missing analysts' expectations. Edgewell Personal Care delivered the weakest performance against analyst estimates in the group. As expected, the stock is down 6.8% since the results and currently trades at $28. Read our full analysis of Edgewell Personal Care's results here. Operating in the emerging beauty health category, the appropriately named BeautyHealth (NASDAQ:SKIN) is a skincare company best known for its Hydrafacial product that cleanses and hydrates skin. BeautyHealth reported revenues of $69.58 million, down 14.5% year on year. This print topped analysts' expectations by 8.9%. Overall, it was a very strong quarter as it also put up a solid beat of analysts' gross margin estimates and an impressive beat of analysts' EBITDA estimates. BeautyHealth delivered the biggest analyst estimates beat among its peers. The stock is up 20.3% since reporting and currently trades at $1.48. Read our full, actionable report on BeautyHealth here, it's free. Known for its Optavia program that combines portion-controlled meal replacements with coaching, Medifast (NYSE:MED) has a broad product portfolio of bars, snacks, drinks, and desserts for those looking to lose weight or consume healthier foods. Medifast reported revenues of $115.7 million, down 33.8% year on year. This number came in 0.6% below analysts' expectations. Taking a step back, it was a mixed quarter as it also recorded an impressive beat of analysts' EPS estimates but revenue guidance for next quarter missing analysts' expectations. Medifast had the slowest revenue growth among its peers. The stock is flat since reporting and currently trades at $12.62. Read our full, actionable report on Medifast here, it's free. Thanks to the Fed's rate hikes in 2022 and 2023, inflation has been on a steady path downward, easing back toward that 2% sweet spot. Fortunately (miraculously to some), all this tightening didn't send the economy tumbling into a recession, so here we are, cautiously celebrating a soft landing. The cherry on top? Recent rate cuts (half a point in September 2024, a quarter in November) have propped up markets, especially after Trump's November win lit a fire under major indices and sent them to all-time highs. However, there's still plenty to ponder — tariffs, corporate tax cuts, and what 2025 might hold for the economy. Want to invest in winners with rock-solid fundamentals? Check out our Hidden Gem Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-05-2025
- Business
- Yahoo
Nature's Sunshine (NASDAQ:NATR) Beats Q1 Sales Targets
Wellness products company Nature's Sunshine (NASDAQ:NATR) reported Q1 CY2025 results beating Wall Street's revenue expectations , with sales up 2% year on year to $113.2 million. The company expects the full year's revenue to be around $457.5 million, close to analysts' estimates. Its GAAP profit of $0.25 per share was 51.5% above analysts' consensus estimates. Is now the time to buy Nature's Sunshine? Find out in our full research report. Nature's Sunshine (NATR) Q1 CY2025 Highlights: Revenue: $113.2 million vs analyst estimates of $109.3 million (2% year-on-year growth, 3.6% beat) EPS (GAAP): $0.25 vs analyst estimates of $0.17 (51.5% beat) Adjusted EBITDA: $10.97 million vs analyst estimates of $9.75 million (9.7% margin, 12.5% beat) The company reconfirmed its revenue guidance for the full year of $457.5 million at the midpoint EBITDA guidance for the full year is $41 million at the midpoint, below analyst estimates of $42.98 million Operating Margin: 5.4%, up from 4.2% in the same quarter last year Free Cash Flow was $1.50 million, up from -$1.50 million in the same quarter last year Market Capitalization: $231 million '2025 got off to a strong start, as first quarter revenue came in at $113 million, up 5% on a constant currency basis, and adjusted EBITDA came in at $11 million, up 20% versus prior year,' said Terrence Moorehead, CEO of Nature's Sunshine. Company Overview Started on a kitchen table in Utah, Nature's Sunshine (NASDAQ:NATR) manufactures and sells nutritional and personal care products. Sales Growth Reviewing a company's long-term sales performance reveals insights into its quality. Any business can have short-term success, but a top-tier one grows for years. With $456.6 million in revenue over the past 12 months, Nature's Sunshine is a small consumer staples company, which sometimes brings disadvantages compared to larger competitors benefiting from economies of scale and negotiating leverage with retailers. As you can see below, Nature's Sunshine struggled to increase demand as its $456.6 million of sales for the trailing 12 months was close to its revenue three years ago. This shows demand was soft, a poor baseline for our analysis. Nature's Sunshine Quarterly Revenue This quarter, Nature's Sunshine reported modest year-on-year revenue growth of 2% but beat Wall Street's estimates by 3.6%. Looking ahead, sell-side analysts expect revenue to grow 1.6% over the next 12 months, similar to its three-year rate. While this projection implies its newer products will fuel better top-line performance, it is still below the sector average.
